TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31888588
Drug: Visit purpose
Normalized name: Corona Multi-Purpose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visit purpose (dental examination or treatment with conscious sedation)
Study: 31889230
Drug: Dotinurad 1
Normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Dotinurad 1 mg (single oral administration)
Study: 31889307
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT), 12-16 sessions
Study: 31890041
Drug: EVO 2.5
Normalized name: Therapevo 2.5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVO 2.5 mg
Study: 31890041
Drug: EVO 5
Normalized name: Stalevo 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVO 5 mg
Study: 31890041
Drug: EVO 10
Normalized name: Stalevo 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVO 10 mg
Study: 31890041
Drug: SITA 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SITA 100 mg
Study: 31890043
Drug: 12-months exercise
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-months exercise program (a combination of aerobic and strength training for a minimum of 150 min per week)
Study: 31890266
Drug: 12-week physical
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week physical activity intervention (4 weekly aerobic and strength training sessions)
Study: 31890902
Drug: V7 TB
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: V7 TB vaccine (10 µg of hydrolyzed heat-killed mycobacteria)
Study: 31890996
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy (LLT) including statin and/or ezetimibe
Study: 31893514
Drug: AAV5-hFVIII-SQ gene
Normalized name: AAV5-hFIXco-Padua
DrugBank: Etranacogene dezaparvovec (DB16791)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV5-hFVIII-SQ gene therapy
Study: 31894377
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT-AFL) treatment in treatment-naïve patients
Study: 31894377
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT-AFL) treatment in previously treated patients
Study: 31894704
Drug: Metronomic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic oral vinorelbine in combination with immune-checkpoint inhibitors
Study: 31895611
Drug: AMG 420
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 420 at 400 μg/d (maximum tolerated dose)
Study: 31895611
Drug: AMG 420
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 420 at 0.2-800 μg/d
Study: 31895611
Drug: AMG 420
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 420 at 800 μg/d
Study: 31895611
Drug: AMG 420
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 420 at 400 μg/d
Study: 31896519
Drug: Lurbinectedin monotherapy
Normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lurbinectedin monotherapy (Stratum C)
Study: 31897676
Drug: Etoposide, methylprednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) combination chemotherapy
Study: 31898493
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) at a low dose of 75μg/d for 1 month, adjusted to 150μg/d if lesions did not improve, for a total treatment duration of 6 months.
Study: 31899729
Drug: Cholic acid
Normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cholic acid (10-15 mg·kg·day)
Study: 31899873
Drug: BBBD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBBD with MR-guided focused ultrasound (MRgFUS) during adjuvant TMZ chemotherapy
Study: 31900121
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg i.v. every 2 weeks for 4 cycles preoperatively with concomitant radiation therapy of bladder and pelvic region (max. 50.4 Gy)
Study: 31903182
Drug: R-CHOP plus
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP plus B-cell receptor/NF-κB-double-targeting
Study: 31905377
Drug: hs-cTnI cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnI cutoff of 2.5 ng/L
Study: 31905377
Drug: hs-cTnT concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT concentrations less than 5 ng/L
Study: 31905377
Drug: hs-cTnI concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnI concentrations less than 2 ng/L
Study: 31907183
Drug: High-Dose Chloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Chloroquine
Study: 31907183
Drug: Standard-Dose Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-Dose Chloroquine
Study: 31907538
Drug: BMD correlation
Normalized name: BACITRACIN METHYLENEDISALICYLATE 50 g in 0.45 kg ORAL GRANULE [BMD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMD correlation with parathyroid hormone, FGF23, thyrotropin, and glycated hemoglobin (HbA1c) levels
Study: 31907737
Drug: Matched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched treatment based on molecular targets
Study: 31908441
Drug: Bronchodilator Responsiveness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchodilator Responsiveness (BDR)
Study: 31908444
Drug: Daily variability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily variability in chest tightness and wheezing
Study: 31908520
Drug: 0.1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ropivacaine combined with 2 μg/kg dexmedetomidine (LD group)
Study: 31908520
Drug: 0.1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ropivacaine (L group)
Study: 31909303
Drug: Tadalafil and
Normalized name: finasteride and tadalafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil and subcutaneous BNP
Study: 31910916
Drug: Supportive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Therapy for Cognitively Impaired Older Adults (ST-CI)
Study: 31912493
Drug: Adjunctive perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive perampanel (mean daily dose 7.0 mg/day)
Study: 31912905
Drug: Neratinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib plus HDAC inhibitors
Study: 31915166
Drug: Intra-arterial thrombectomy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial thrombectomy (IAT) with intravenous thrombolysis (IVT) at the nearest primary stroke centre (PSC)
Study: 31915192
Drug: Gentamicin exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin exposure (6 mg/kg)
Study: 31918324
Drug: Model with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model with improved variables (progesterone and oestrogen receptor expression, method of sample extraction)
Study: 31918531
Drug: Energy Conservation
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy Conservation plus Problem-Solving Therapy
Study: 31919092
Drug: Inhibitor development
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitor development in patients with SHB
Study: 31919092
Drug: Allergic reactions
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergic reactions in inhibitor patients
Study: 31919092
Drug: Genotype association
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype association with inhibitors
Study: 31919404
Drug: FOLFIRINOX every
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX every 2 weeks (adapted dose in stage two)
Study: 31920571
Drug: KINVIS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: KINVIS therapy combined with conventional therapeutic exercise (TherEX) for 10 days
Study: 31920571
Drug: KINVIS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: KINVIS therapy combined with conventional therapeutic exercise (TherEX)
Study: 31920733
Drug: Lanicemine, NMDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanicemine, NMDA receptor antagonist, dosage and duration not available
Study: 31922084
Drug: SC +
Normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC + Enhanced Program (SC + EP; 8 skill-building cores, monthly support sessions, targeted diet/physical activity strategies)
Study: 31922545
Drug: OAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC with vitamin K antagonists
Study: 31922545
Drug: OAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC with vitamin K antagonists, clinically significant depressive symptoms (PHQ-2 ≥ 3)
Study: 31923098
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (n=1617)
Study: 31923098
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (n=2658)
Study: 31923098
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (n=1810)
Study: 31923800
Drug: NGS matched
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGS matched therapy
Study: 31924241
Drug: Reparixin 1000
Normalized name: Réparixine
DrugBank: Reparixin (DB12614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reparixin 1000 mg orally three times daily for 21 days before surgery
Study: 31928530
Drug: C3 administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C3 administration in GC cell lines
Study: 31928530
Drug: C3 blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C3 blocker pre-incubation
Study: 31928530
Drug: JAK2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: JAK2 inhibitor pre-treatment
Study: 31929554
Drug: Incentive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive and information tracks of the intervention; specific details on dosage and duration not available.
Study: 31929554
Drug: Community-based recruitment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based recruitment strategy; specific details on dosage and duration not available.
Study: 31929554
Drug: Management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of inputs at the facility and patient level; specific details on dosage and duration not available.
Study: 31930057
Drug: Sertraline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (75 mg/day)
Study: 31930095
Drug: Oral Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chinese Medicine (CM) herbal medication administered twice daily for eight weeks.
Study: 31930374
Drug: Ambroxol therapy
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol therapy (1.26 g per day)
Study: 31931024
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell (DC)-based active cellular immunotherapy using high hydrostatic pressure-killed cancer cells derived from NSCLC cell lines.
Study: 31932137
Drug: gp120-NefTat/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp120-NefTat/AS01 vaccine
Study: 31932382
Drug: Linezolid treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid treatment, specific dosage and duration not available
Study: 31932515
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg oral tablets
Study: 31932515
Drug: Erenumab 70
Normalized name: Erenumab 70 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 70 mg subcutaneous monthly
Study: 31932515
Drug: Erenumab 140
Normalized name: Erenumab 140 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 140 mg subcutaneous monthly
Study: 31932515
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg oral tablets and Erenumab
Study: 31934594
Drug: Subacromial 10-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial 10-mL 2% lidocaine injection
Study: 31934594
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (no contents injected)
Study: 31934829
Drug: Radiofrequency ablation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency ablation (RFA) treatment, 88 sessions from January 2008 to April 2014.
Study: 31936256
Drug: Questionnaire items
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Questionnaire items addressing Oral Health Locus of Control (OHLOC)
Study: 31937310
Drug: Caverstem 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caverstem 1.0 low dose
Study: 31937310
Drug: Caverstem 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caverstem 1.0 high dose
Study: 31937474
Drug: CAREN system
Normalized name: 3-carene
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAREN system (8 sessions, twice weekly for 4 weeks)
Study: 31937616
Drug: GDC-0084 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0084 (45 mg/day)
Study: 31937616
Drug: GDC-0084 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0084 (various doses)
Study: 31937616
Drug: GDC-0084 (≥45
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0084 (≥45 mg/day)
Study: 31941657
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in the 1970s
Study: 31941657
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in the 1980s
Study: 31941657
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in the 1990s
Study: 31941953
Drug: Fingolimod (FTY)
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fingolimod (FTY) treatment
Study: 31942173
Drug: Cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg once daily for 2 years
Study: 31942173
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg once daily for 2 years
Study: 31942430
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection (IVI) of anti-VEGF (bevacizumab or ranibizumab) followed by a loose treat and extend regimen.
Study: 31942430
Drug: Rescue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy of aflibercept (Group 2).
Study: 31942430
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with three loading doses of either bevacizumab or ranibizumab.
Study: 31943126
Drug: Near-infrared fluorescence
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Near-infrared fluorescence imaging with indocyanine green (ICG) administered intravenously at 0.3 mg/kg bodyweight.
Study: 31943126
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of white-light and NIR-ICG.
Study: 31943691
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) use
Study: 31943974
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg (with dose escalation to 300 mg)
Study: 31943974
Drug: Secukinumab (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (any dose)
Study: 31945475
Drug: Post-bronchodilator response
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-bronchodilator response (BDR) measurements
Study: 31948451
Drug: BPI-9016M (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPI-9016M (100 mg to 800 mg, QD dosing for 28 days)
Study: 31950432
Drug: YAZ (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: YAZ (3 mg drospirenone/20 μg ethinyl estradiol)
Study: 31952975
Drug: Cemiplimab 3
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 3 mg/kg intravenously over 30 min every 2 weeks for up to 96 weeks
Study: 31954100
Drug: Oral colistin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral colistin and neomycin decontamination
Study: 31954624
Drug: Nazartinib (EGF816)
Normalized name: Lazertinib
DrugBank: Nazartinib (DB16250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nazartinib (EGF816) 150 mg once daily (tablet)
Study: 31956341
Drug: Diabetic foot
Normalized name: Zostrix Diabetic Foot Pain
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diabetic foot ulcer treatment
Study: 31956421
Drug: Dynamic LED
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic LED lighting for 4 weeks in addition to standard treatment
Study: 31956421
Drug: Static LED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static LED lighting for 4 weeks in addition to standard treatment
Study: 31956432
Drug: Intravitreal ziv-aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ziv-aflibercept (IVZ) 1.25 mg
Study: 31956961
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tofogliflozin
Study: 31956961
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg glimepiride
Study: 31958302
Drug: NGT-1-hour-high (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGT-1-hour-high (glucose ≥8.6 mmol/L)
Study: 31958302
Drug: NGT-1-hour-normal (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGT-1-hour-normal (glucose <8.6 mmol/L)
Study: 31958302
Drug: One-hour glucose
Normalized name: ONE TOUCH (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-hour glucose concentration ≥8.6 mmol/L
Study: 31959034
Drug: hs-cTnT levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT levels >14 ng/L at anthracycline completion
Study: 31960589
Drug: Amphetamine-type stimulants
Normalized name: AMPHETAMINE LIKE STIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine-type stimulants use in the past six months
Study: 31960953
Drug: Peroperative carcinoembryonic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroperative carcinoembryonic antigen (CEA)-specific fluorescence imaging during cytoreductive surgery-hyperthermic intraperitoneal chemotherapy
Study: 31961766
Drug: Lenvatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib plus pembrolizumab (200 mg intravenously every 3 weeks)
Study: 31961766
Drug: Lenvatinib 20
Normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 20 mg/d plus pembrolizumab (recommended phase II dose)
Study: 31961766
Drug: Lenvatinib 24
Normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 24 mg/d plus pembrolizumab (initial dose level)
Study: 31961766
Drug: Subsequent dose-de-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent dose-de-escalation cohort (lenvatinib 20 mg/d plus pembrolizumab)
Study: 31961826
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mirabegron for 4 weeks
Study: 31961829
Drug: Mirabegron treatment
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron treatment
Study: 31964784
Drug: CUE-101, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUE-101, a novel therapeutic fusion protein composed of a human leukocyte antigen (HLA) complex, an HPV16 E7 peptide epitope, reduced affinity human IL2 molecules, and an effector attenuated human IgG1 Fc domain.
Study: 31969330
Drug: ABBV-838 (3+3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-838 (3+3 design) intravenously starting from 0.6 mg/kg up to 6.0 mg/kg for 3-week dosing intervals (Q3W), continued for up to 24 months.
Study: 31969338
Drug: Decitabine and
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine and Vorinostat with chemotherapy (vincristine, dexamethasone, mitoxantrone, PEG-asparaginase)
Study: 31971541
Drug: Talimogene laherparepvec
Normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Talimogene laherparepvec (T-VEC) plus pembrolizumab (200-mg flat dose) intravenously; T-VEC first dose ≤4 mL × 106 PFU/mL, subsequent doses ≤4 mL × 108 PFU/mL, injected into palpable tumor site(s) on day 1 of each 21-day cycle.
Study: 31971567
Drug: IV posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV posaconazole 300 mg
Study: 31971567
Drug: IV posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV posaconazole 400 mg
Study: 31972008
Drug: rs9349379-G allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs9349379-G allele
Study: 31972008
Drug: Zibotentan (ETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan (ETA antagonist)
Study: 31972009
Drug: ST2 (>26
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST2 (>26 ng/mL) in children age 10 years or younger